Sumit Lal, PhD

Junior Faculty (Instructor) in Medicine
Department of Medicine
Harvard Medical School
221 Longwood Avenue
Boston, Massachusetts 02115-5730, USA


Dr. Lal is an expert in the field of inorganic nanomedicine. Dr. Lal has generated more than 20 research articles and participated in more than $1M funding in the past 5 years. He is the recipient of prestigious John Gavin Fellowship by Genesis Energy, New Zealand in 2012. To-date, he has been awarded $590,000 in the form of 8 funding awards that include competitively won fellowships and scholarships. Dr. Lal is on the editorial board of Journal of Biomimetics, Biomaterials, and Tissue Engineering, OMICS (Impact factor (IF): 2.3) and Research Journal of Materials Research and Technology, Elsevier (IF: 1.5). He is also peer reviewer for more than 10 journals including Biomaterials (IF: 8.5), Nature Biotechnology (IF: 31) and Advance functional Materials (IF: 10). Dr. Lal is presently a Junior Faculty at Harvard Medical School. Prior to this, he completed three postdoctoral assignments (fellowships) at The Department of Cell Biology, Harvard Medical School and Nephrology Division, Department of Medicine, Massachusetts General Hospital and Brigham & Womens Hospital. He holds PhD in Chemistry from, New Zealands leading, The University of Auckland.


Academic Positions

• Junior Faculty (Instructor / Lecturer), Department of Medicine, Harvard University (August 2012-present)
• Research fellow, Department of Cell Biology, Harvard University. (November 2011- July 2012)
• Research fellow, Department of Medicine, Massachusetts General Hospital, Brigham & Womens Hospital and Harvard Medical School. (September 2009-October 2011)
• Research Associate, Department of Chemistry, The University of Auckland. (August 2004-January 2007)
• Non Academic (Industry) Appointments Doctoral Fellow, Fonterra co-operative Ltd, Hamilton, New Zealand (March 2007-August 2009)
• Research Associate, Climate Coatings Ltd, Auckland, New Zealand (August 2005 Jan 2006)
• Summer Research Fellow, LG Chemicals Ltd, Daejon, South Korea (May 2003-July 2003)

Research Interest

His research interests include: Utilization of titanium dioxide, Gold and iron oxide nanoparticles (SPIONs) for development of novel drug delivery platforms, medical implants, Biosensors and Lab on a chip platforms.

Scientific Activities


• Prestigious Fellowship and Scholarships ($590K) John Gavin Fellowship in Oncology Genesis Energy, New Zealand, (2012)
• Otago University Fellowship  Otago University, Christchurch, New Zealand, (2012)
• NSF funded – Postdoctoral Fellowship in Cell Biology  Harvard Medical School, USA, (2011)
NIH funded – Research Fellowship in Molecular Physiology Massachusetts General Hospital, USA, (2010)
• Bright Future Scholarship  TEC and Fonterra co-operative Ltd, New Zealand, (2007) 
• Bio composites Research Funding Biopolymer network, New Zealand, (2005)
• Summer Undergraduate Fellowship LG Chemicals, S. Korea, (2003)
• Summer and Winter Undergraduate Fellowship  Pohang University of Science & Technology, S. Korea, (2002) Grants (Total participated: $1.05M)
• Development Program in Cellular Dynamics and Function National Science Foundation, USA, (2011-2012)  (PI: Avidor-Reiss T.) 
• American Recovery and Reinvestment Act (ARRA) Award The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), USA, (2010-2011)  (PI: Cantiello H.) 



1. Verma J, Lal S, Van Veen H, Van Noorden CJF. A novel strategy for synthesis of gold nanoparticle self assemblies. Curr Nanosci. 2014; 10: 670-675. doi: 10.2174/1573413710666140526232145
2. Verma J, Van Veen H, Lal S, Van Noorden CJF. Wet chemistry approaches for synthesis of gold nanospheres, nanorods and nanostars. Curr Nanosci. 2014; 10: 660-669. doi: 10.2174/1573413710666140526232421
3. Verma J, Lal S, Van Noorden CJF. Nanoparticles for hyperthermic therapy: Synthesis strategies and applications in glioblastoma. Int J Nanomed. 2014; 9: 2863-2877. doi: 10.2147/IJN.S57501
4. Kanazirska MV, Fuchs PM, Chen L, Lal S, Verma J, Vassilev PM. Beneficial effects of Lysosome-modulating and other Pharmacological and Nanocarrier Agents on Amyloidbeta- treated cells. Curr Pharm Biotechnol. 2012; 13(15): 2761-2767.
5. Lal S, Verma J, Easteal AJ. Self Sterilizing Titanium dioxide Incorporated Wound Healing Membrane. Nanoengineering Part A. 2013; (9).
6. Verma J, Lal S, Eastael AJ. Process to Manufacture cross-linked Gelatin Microfibers. Nanoengineering Part A. 2013; (9).
7. Paracha R, Lal S, Verma J, Easteal AJ. High Strength Nanocomposites from Powder Coating Resin, Lignin and Saw Flour. World Journal of Engg. 2009; (6): 783-786.
8. Lal S, Edmonds N, Easteal AJ. Properties of Glycerol Plasticized Whey Films Modified by Guanidine Thiocynate. World Journal of Engg. 2009; (6): 529-532.


9. Lal S, Freidman D. F1000Prime Recommendation of [Benilova I. et al. Nature Neurosci. 2012; 15(3): 349-357.
10. Lal S, Freidman D. Naturally secreted oligomers of amyloid bold beta protein potently inhibit hippocampal long-term potentiation in vivo. F1000Prime Recommendation of Walsh DM, Klyubin I, Fadeeva JV, et al. Nature. 2002; 416(6880): 535-539. doi: 10.1038/416535a
11. Lal S, Freidman D. Structural conversion of neurotoxic amyloid-beta(1-42) oligomers to fibrils. F1000Prime Recommendation of Ahmed M, Davis J, Aucoin D, et al. Nat Struct Mol Biol. 2010; 17(5): 561-567. doi: 10.3410/f.718010839.793476819
12. S. Lal and D. F1000Prime Recommendation of [Bieschke J. et al. Nature Chem Biol. 2012; 2012: 101038.
13. Lal S, Freidman D. Conjugated Quantum Dots Inhibit the Amyloid β (1-42) Fibrillation Process. F1000Prime Recommendation of Thakur G, Micic M, Yang Y, et al. Int J Alzheimers Dis. 2011; 2011: 502386. doi: 10.3410/f.717989866.793473065
14. Lal S, Freidman D. Conformational differences between two amyloid β oligomers of similar size and dissimilar toxicity. F1000Prime Recommendation of Ladiwala AR, Litt J, Kane RS, et al. J Biol Chem. 2012; 287(29): 24765-24773. doi: 10.3410/f.717972974.793469783